EyeBio closes Series A financing extension with $130 million
Click Here to Manage Email Alerts
Key takeaways:
- The proceeds will support the company’s clinical development program and retina pipeline.
- Enrollment is complete the phase 1b/2a AMARONE clinical trial of Restoret.
EyeBio closed an extension to its Series A financing, ending with $130 million raised, according to a press release.
The proceeds will help accelerate the company’s clinical development program and build out its retina pipeline.
Image: Adobe Stock
New investors included Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC, with participation from existing investors SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund.
EyeBio also announced the completion of enrollment in the multiple ascending dose portion of the phase 1b/2a AMARONE clinical trial of Restoret in patients with diabetic macular edema and neovascular age-related macular degeneration.
“Completion of part 1 of the AMARONE trial is a major achievement for EyeBio and represents a significant milestone in our effort to bring innovative therapies to patients with retinal diseases,” Tony Adamis, MD, chief scientific officer and co-founder of EyeBio, said in the release. “We hear constantly from retinal physicians about the need to drive better outcomes for their patients and the demand for novel approaches to treating serious retinal diseases. Restoret may be one such approach. It’s a first-in-class Wnt pathway agonist antibody that we hope can improve the outcomes and lives of patients with diabetic macular edema and neovascular age-related macular degeneration.”
Click Here to Manage Email Alerts